Eisai/Pfizer Get Complete Response For Alzheimer's Patch
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants more details about the Aricept patch before it issues an approval.
You may also be interested in...
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training
Pfizer And Eisai Will Continue To Promote Aricept, But Add Lyrica To The Collaboration
After Eisai tried to get out of its co-promotion deal for the Alzheimer’s disease blockbuster, the two companies settle their dispute with Japanese rights to Aricept returning to Eisai sooner than originally planned.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.